Brian Lee, MD
Transplant Hepatology · San Bernardino, CANPI 1346583242
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,093 of the $35,437 with a category attached, or 82.1%. Novo Nordisk accounts for 84.9% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $17,133 and has fallen 83.2% since, to $2,873 in 2025.
Across 46 payments — averaging $770.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$30K
- Cook Incorporated$2K
- Novo Nordisk AS$2K
- Gilead$339
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$249
- Osteomed LLC$157
- plus $659 from 8 others
What the payments were for
- Consulting fees$29,09382%
- Speaking & faculty fees$2,3507%
- Travel & lodging$2,3297%
- Food & beverage$1,5094%
- Education$1570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $30,098 |
| Cook Incorporated | 1 | $2,350 |
| Novo Nordisk AS | 2 | $1,586 |
| Gilead | 10 | $339 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $249 |
| Osteomed LLC | 1 | $157 |
| Ipsen Biopharmaceuticals, Inc | 3 | $140 |
| AbbVie | 2 | $136 |
| Mallinckrodt Hospital Products Inc. | 1 | $122 |
| Histosonics, Inc. | 1 | $120 |
| Madrigal Pharmaceuticals | 1 | $50 |
| Intercept Pharmaceuticals, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Albireo Pharma, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ECHOTIP INSIGHT$2,350
- CMF-CFx$157
- TERLIVAZ$122
- Mavyret$119
How this compares
$35,437 in reported general payments places this provider in the 75th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 58 | $182,393 |
| VemlidyTenofovir Alafenamide | 29 | $42,611 |
| Ursodiol | 91 | $12,737 |
| Entecavir | 43 | $10,027 |
| Tenofovir Disoproxil Fumarate | 50 | $5,387 |
| Spironolactone | 100 | $950 |
| ConstuloseLactulose | 11 | $837 |
| Lactulose | 21 | $700 |
| Azathioprine | 18 | $674 |
| Pantoprazole Sodium | 52 | $480 |
| Carvedilol | 112 | $425 |
| Furosemide | 102 | $363 |
| Prednisone | 25 | $296 |
| Omeprazole | 31 | $257 |
| Bumetanide | 14 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $249 | $182,39358 claims |
| GileadVemlidy | $339 | $42,61129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 transplant hepatology providers in California.
Other transplant hepatology in San Bernardino
- Julio GutierrezLos Angeles$895K
- Pei Lim LeeLos Angeles$79K
- Jennifer LaiSan Francisco$70K
- Kidist YimamSan Francisco$53K
- Beshoy YannyLos Angeles$50K
- Kali ZhouLos Angeles$50K
- Mindie NguyenStanford$50K
- Jasleen SinghLos Angeles$46K
- Bilal HameedSan Francisco$44K
- Norah TerraultLos Angeles$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.